Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Vertex Expands Its Pipeline

Yesterday, Rule Breakers pick Vertex Pharmaceuticals (Nasdaq: VRTX  ) released its third-quarter financial results and updated investors on the progress with its pipeline.

The most interesting revelation from the conference call and earnings release was that Vertex is planning on advancing a second-generation protease inhibitor into the clinic by the end of 2007. This is a smart move, since viral resistance is likely to occur in some subset of patients infected with hepatitis C virus (HCV) and treated with its lead drug candidate telaprevir.

On the conference call, Vertex's management said it was looking to build a pipeline of anti-HCV products. However, it's not clear if this was just a comment about the second protease inhibitor, or an indication that Vertex would start developing compounds targeting the other steps of HCV life cycle, like polymerase inhibitors.

If Vertex is looking to build a portfolio of HCV-fighting drugs along the lines of Roche or Gilead Sciences (Nasdaq: GILD  ) , then it's likely going to have to do the drug development work in-house rather than by signing partnership deals, as there are few unpartnered promising clinical stage HCV antiviral compounds available. Or it could just sign a deal for Flamel Technologies' (Nasdaq: FLML  ) improved interferon drug candidate.

If Vertex does develop drugs targeting different aspects of the hepatitis C virus and its second protease inhibitor treatment is successful, it will help to cement Vertex's leading role in antiviral drug development. There's also the possibility that Vertex's second protease inhibitor could be more potent or have fewer side effects than telaprevir. That's something that would keep the cash rolling in for a long time.

More Foolish thoughts on HCV:

Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 539415, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:19:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
VRTX $78.71 Down +0.00 +0.00%
Vertex Pharmaceuti… CAPS Rating: ****
FLML $11.11 Down -0.47 -4.06%
Flamel Technologie… CAPS Rating: ***
GILD $75.38 Up +0.97 +1.30%
Gilead Sciences CAPS Rating: *****